Gilead buying Cell Design Labs for $567m in further CAR T boost

By Staff Reporter

- Last updated on GMT

GettyImages/BsWei
GettyImages/BsWei

Related tags: T cell, Major histocompatibility complex, Protein

Months after jumping into the cell therapy space through the $11.9bn acquisition of Kite, Gilead has agreed to buy CAR T tech firm Cell Design Labs.

In August​, Gilead Sciences acquired Kite for $11.9bn (€10.1bn) and launched itself in the chimeric antigen receptor (CAR) T-cell. Since then, the firm received regulatory approval for its lead product Yescarta (axicabtagene ciloleucel)​ and is now expanding its capabilities in the CAR T space through the acquisition of Cell Design Labs.

Kite Pharma has worked with Cell Design Labs for almost 18 months and integrated its Throttle Switch technology into its CAR T-cell pipeline.

The platform is a precision control tool, enabling a physician to turn CAR T-cells on and off repeatedly, which the firm says allows them to be better tolerated and more effective.

“This is achieved by splitting a standard CAR-T molecule construct into two separate, and inactive, molecular components and cloning these into a patient’s T cell, resulting in the CAR-T cell existing in an ‘off’ state,”​ the firm said.  

“Only in the presence of an FDA-approved small molecule drug will the two components come together – closing the ‘switch’ - into an active state, seeking out and eliminating cancer cells.”

The acquisition will also see Gilead add Cell Design Labs’ synNotch Receptors platform consisting of the reengineering of portions of the naturally occurring Notch receptor making it so a patient’s T cells can be instructed to detect new molecular targets and turn on new genes.

“Bringing our robust technology platforms under the Gilead umbrella, with its outstanding research and development capabilities and commitment to innovation, provides an exciting path forward for the development of the next generation of living therapies for patients with cancer,”​ said Brian Atwood, CEO of Cell Design Labs.

The structured buyout valued at as much as $567m, including the shares of Cell Design Labs held by Kite.

Related news

Show more

Related products

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars